Friday, September 5, 2014

How Can You Better Predict Immunogenicity?

Calculating immunogenicity directly effects your company's bottom line from drugs failing in the clinic to denying patients crucial treatment. Furthermore, the risk of adverse reactions is always existing when creating your product.  

Your company is searching for the Holy Grail to reduce or remove immunogenicity completely from its products. Assessment of immunogenicity continues to be hindered by complications such as pre-existing antibody, manual flow cytometry workflow, and drug interference while interpretation of data is complicated.

IIR's 15th Annual Immunogenicity of Biotherapeutics has a half day dedicated to predicting immunogenicity through a better understanding of underlying causes. You'll also learn about new procedures to adopt to save you money, time, and minimize the immunogenic potential in discovery.

Featured Sessions:

 Next Generation Assays for Immunogenicity Prediction
    Pedro Paz, BR-US-Lead Discovery-Immunoassay/Immunoprofiling Group, Bayer HealthCare LLC

-  Prediction of Clinical Immunogenicity of Adnectins: Guiding Lead Optimization
    Daron Forman, Principal-Scientist, Bristol-Myers-Squibb

-  Improvement of a Sample Pretreatment Procedure for Immunogenicity Testing through Better Characterization of Cells, Positive Control Antibodies and Residual Drug Level
    Weifeng Xu, Research Investigator, Bristol-Myers-Squibb

Download the agenda to see what else is on tap.
Reserve your seat alongside your peers from Sanofi-Genzyme, Shire Human Genetic Therapies (HGT), Boehringer Ingelheim GmbH, and many more already confirmed!  SAVE $100 when you register here and use code XP1938BLOG.

Don’t miss a thing. Sign up for our updates
Follow us on Twitter
Join us on LinkedIn

Share this article with your social network, just click below to share now!

No comments :

Post a Comment